Holen Sie sich die Stockscreener-App
203.10
1.16%
-2.39
Vorhandelsmarkt:
204.50
1.40
+0.69%
Schlusskurs vom Vortag:
$205.49
Offen:
$205.68
24-Stunden-Volumen:
299.54K
Relative Volume:
0.36
Marktkapitalisierung:
$10.64B
Einnahmen:
$708.24M
Nettoeinkommen (Verlust:
$-188.30M
KGV:
-54.32
EPS:
-3.7392
Netto-Cashflow:
$-70.99M
1W Leistung:
-0.48%
1M Leistung:
-2.25%
6M Leistung:
+29.43%
1J Leistung:
+72.87%
1-Tages-Spanne:
$202.52
$207.01
1-Wochen-Bereich:
$201.94
$216.47
52-Wochen-Spanne:
$115.31
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
203.10 | 11.56B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
About Axsome Therapeutics, Inc. rStock - Coinbase
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2036 – DelveInsight | Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Lab, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’ - Stocktwits
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 7%Should You Buy? - MarketBeat
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Axsome Therapeutics, Inc. $AXSM Shares Bought by California State Teachers Retirement System - MarketBeat
Axsome at cantor healthcare conference: auvelity growth accelerates By Investing.com - Investing.com South Africa
Transcript : Axsome Therapeutics, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02 - marketscreener.com
AXSM: AUVELITY's commercial expansion and deep pipeline position the company for strong near-term growth - TradingView
Axsome at cantor healthcare conference: auvelity growth accelerates - investing.com
AXSM: AUVELITY's rapid growth and robust CNS pipeline position the company for significant expansion - TradingView
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Axsome Therapeutics Inc (19X) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics (AXSM) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Axsome Therapeutics at Wells Fargo conference: growth broadens By Investing.com - Investing.com South Africa
Axsome Therapeutics Inc (19X) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Axsome reports strong growth for its CNS drugs ... - Pluang
Axsome Therapeutics Inc (19X) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
AXSM: AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials - TradingView
Transcript : Axsome Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03 - marketscreener.com
Axsome Therapeutics at Wells Fargo conference: growth broadens - investing.com
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
The Technical Signals Behind (AXSM) That Institutions Follow - Stock Traders Daily
Hsbc Holdings PLC Sells 12,653 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Is Axsome Therapeutics (NASDAQ:AXSM) Entering A Turning Point? - Kalkine Media
33,554 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Readystate Asset Management LP - MarketBeat
Axsome Therapeutics (AXSM) Investor Outlook: Unveiling a 38% Upside Potential Amidst Rapid Growth in CNS Therapies - DirectorsTalk Interviews
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Seven Fleet Capital Management LP Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
12,293 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Public Employees Retirement System of Ohio - MarketBeat
Corient Private Wealth LP Makes New $1.26 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome therapeutics COO Mark Jacobson sells $2.08m of company stock - Investing.com Nigeria
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Axsome Therapeutics (AXSM) Institutional Ownership 2026 - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $2,086,500.00 in Stock - MarketBeat
Axsome Therapeutics (AXSM) COO sells 10,000 shares in pre-set trading plan - Stock Titan
Planned $2.1M Axsome Therapeutics (AXSM) stock sale set under pre-arranged trading plan - Stock Titan
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $256 - moomoo.com
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - The Globe and Mail
Axsome Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Legal & General Group Plc Makes New $8.10 Million Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Van ECK Associates Corp Has $7.17 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
20,091 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Alyeska Investment Group L.P. - MarketBeat
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation - Yahoo Finance
Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says - marketscreener.com
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jacobson Mark L. | Chief Operating Officer |
Sep 03 '26 |
Sale |
208.65 |
10,000 |
2,086,500 |
0 |
0.14%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):